Table 1 Relationship between basigin-2 expression with clinicopathological features of patients
Characteristic | No. | Basigin-2 expression | P | |
|---|---|---|---|---|
Low (n%) | High (n%) | |||
Age | Â | Â | Â | 0.683 |
<60 | 95 | 34 (35.8) | 61 (64.2) | Â |
≥60 | 51 | 20 (39.2) | 31 (60.8) |  |
FIGO stage | Â | Â | Â | 0.412 |
I+II | 48 | 20 (41.7) | 28 (58.3) | Â |
III+IV | 98 | 34 (34.7) | 64 (65.3) | Â |
Grade | Â | Â | Â | 0.478 |
G1 | 27 | 12 (44.4) | 15 (55.6) | Â |
G2 | 45 | 18 (40.0) | 27 (60.0) | Â |
G3 | 74 | 24 (32.4) | 50 (67.6) | Â |
Histological type | Â | Â | Â | 0.564 |
Serous | 64 | 22 (34.4) | 42 (65.6) | Â |
Nonserous | 82 | 32 (39.0) | 50 (61.0) | Â |
LVS involvement | Â | Â | Â | 0.012* |
Negative | 120 | 50 (41.7) | 70 (58.3) | Â |
Positive | 26 | 4 (15.4) | 22 (84.6) | Â |
Lymph node metastasis | Â | Â | Â | 0.017* |
Negative | 111 | 47 (42.3) | 64 (57.7) | Â |
Positive | 35 | 7 (20.0) | 28 (80.0) | Â |